Skip to main content

Table 1 Patient and tumor characteristics in the GTF2I mutant and wild-type group

From: Thymic epithelial tumors: examining the GTF2I mutation and developing a novel prognostic signature with LncRNA pairs to predict tumor recurrence

Variables

GTF2I Mutation/

N = 56 (100%)

Wild type/

N = 63 (100%)

p-value

Gender

  

0.855

 Female

26 (46.4)

31 (49.2)

 

 Male

30 (53.6)

32 (50.8)

 

Age

  

0.232

 Mean(±SD)

58.46(±13.32)

55.43(±14.13)

 

Race

  

0.331

 Hispanic or latino

3 (5.4)

7 (11.1)

 

 Not hispanic or latino

53 (94.6)

56 (88.9)

 

MG histoty

  

0.003

 Yes

8 (14.3)

27 (42.9)

 

 No

46 (82.1)

35 (55.6)

 

 Unknown

2 (3.6)

1 (1.6)

 

Masaoka stage

  

0.039

 I

23 (41.1)

13 (20.6)

 

 II

24 (42.9)

36 (57.1)

 

 III

4 (7.1)

11 (17.5)

 

 IV

3 (5.4)

3 (4.8)

 

 Unknown

2 (3.6)

0 (0)

 

Pathologic type

  

< 0.001

 Type A

14 (25.0)

2 (3.2)

 

 Type AB

27 (48.2)

8 (12.7)

 

 Type B1

3 (5.4)

11 (17.5)

 

 Type B2

7 (12.5)

24 (38.1)

 

 Type B3

3 (5.4)

9 (14.3)

 

 Thymic carcinoma

2 (3.6)

9 (14.3)

 

Radiation therapy

  

0.004

 Yes

10 (17.9)

27 (42.9)

 

 No

44 (78.6)

31 (49.2)

 

 Unknown

2 (3.6)

5 (7.9)

 

Vital status

  

0.17

 Dead

2 (3.6)

7 (11.1)

 

 Alive

54 (96.4)

56 (88.9)

 
  1. Abbreviation: MG myasthenia gravis